摘要
目的探讨间变性淋巴瘤激酶(anaplastic lymphoma kinase,ALK)在晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)中的表达,及其与临床特征、鉴别诊断、预后的关系。方法采用免疫组化法检测253例晚期NSCLC中ALK的表达,并对其中132例进行荧光PCR法验证。结果采用免疫组化法检测晚期NSCLC中ALK阳性率为20.95%(53/253)。ALK阳性组中未吸烟者、腺癌的比例高于ALK阴性组(P<0.05)。132例进行荧光PCR验证,免疫组化与荧光PCR符合率随免疫组化阳性程度的增加而递增。结论免疫组化可作为ALK的筛查手段,提高ALK的检出率。荧光PCR检测对ALK阳性NSCLC的确诊具有重要意义。
Purpose To investigate the clinical pathological features of anaplastic lymphoma kinase （ALK） positive advance non-small cell lung cancer （NSCLC） and significance of immunohistochemical （IHC） method in screening ALK positive cases. Methods IHC analysis of ALK in tumor specimens was performed in 253 advance NSCLC cases. 132 cases among them were confirmed by fluorescent polymerase chain reaction （PCR）. Results The positive incidence of ALK by IHC was 20. 95% （53/253）. The ALK positive pa- tients had more non-smoker than that of ALK negative patients （ P 〈 0. 05 ） , and ad was predominant （ P 〈 0. 05 ）. Fluo- rescent PCR was applied in 132 cases. The coincidence rate increased with positive intensity of IHC staining. Conclusion IHC is a reliable method to screen the ALK in lung cancer, and then increase its positive ratio. Fluorescent PCR plays a significant role in mak- ing a definite diagnosis of ALK positive NSCLC.
出处
《临床与实验病理学杂志》
CAS
CSCD
北大核心
2014年第10期1135-1138,共4页
Chinese Journal of Clinical and Experimental Pathology
关键词
肺肿瘤
非小细胞肺癌
间变性淋巴瘤激酶
免疫组织化学
荧光PCR
lung neoplasms
non-small cell lung cancer
anaplastic lymphoma kinase
immunohistochemistry
fluorescence polymer-ase chain reaction
